Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 10/20 | 1.00 |
| ▸ | CDK2 | P24941 | 10/20 | 1.00 |
| ▸ | CDK1 | P06493 | 6/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 5/20 | 1.00 |
| ▸ | FLT3 | P36888 | 4/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.81 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.81 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.78 |
| ▸ | CDK9 | P50750 | 4/20 | 0.78 |
| ▸ | STK17B | O94768 | 3/20 | 0.60 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.60 |
| ▸ | GSK3B | P49841 | 5/20 | 0.56 |
| ▸ | GSK3A | P49840 | 4/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | SGK1 | O00141 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309734 | 0.89 | CDK5R1 (1.00) | CCNE1CDK2CDK1CCNB1FLT3 | |
| Indirubin-3-Monoxime SCHEMBL29354191 | 0.70 | CDK5R1 (1.00) | CCNE1CDK2CDK1CCNB1FLT3 | |
| SCHEMBL29484209 | 0.69 | GSK3B (1.00) | CCNE1CDK2CDK1CCNB1FLT3 | |
| SCHEMBL30319828 | 0.69 | CDK5R1 (1.00) | CCNE1CDK2CDK1CCNB1FLT3 | |
| SCHEMBL30319818 | 0.69 | GSK3B (0.83) | CCNE1CDK2CDK1CCNB1FLT3 | |
| SCHEMBL30319823 | 0.69 | CCNE1 (0.63) | CCNE1CDK2CDK1CCNB1FLT3 | |
| SCHEMBL30141665 | 0.69 | CDK5R1 (1.00) | CCNE1CDK2CDK1CCNB1FLT3 | |
| SCHEMBL29540314 | 0.67 | GABRA1 (0.70) | MEN1NPC1ALDH1A1LMNAMAPT | |
| SCHEMBL155013 | 0.67 | GABRA1 (0.70) | MEN1NPC1ALDH1A1LMNAMAPT | |
| SCHEMBL13302321 | 0.66 | SLC6A4 (0.52) | CCNE1CDK2CDK1CCNB1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293413-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2024-09-05 | — | — | US | claimed |
| EP-4353236-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | OnQuality Pharmaceuticals China Ltd. (CN) | 2024-04-17 | — | — | EP | claimed |
| CN-117529322-A | Compounds and methods for treating chemotherapy-related gastrointestinal side effects | 上海岸阔医药科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2023090935-A1 | METHOD FOR PRODUCING AGM PEPTIDES THAT BIND SPECIFICALLY TO NUCLEOLIN | 애니젠 주식회사 | 2023-05-25 | — | — | WO | claimed |
| WO-2022258001-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | 上海岸阔医药科技有限公司 | 2022-12-15 | — | — | WO | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-20250188545-A1 | METHODS FOR PREDICTING RESPONSIVENESS OF LYMPHOMA TO DRUG AND METHODS FOR TREATING LYMPHOMA | CELGENE CORPORATION (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025080543-A1 | METHODS FOR PREDICTING RESPONSIVENESS OF LYMPHOMA TO DRUG AND METHODS FOR TREATING LYMPHOMA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4508246-A1 | METHODS FOR PREDICTING RESPONSIVENESS OF LYMPHOMA TO DRUG AND METHODS FOR TREATING LYMPHOMA | CELGENE CORPORATION (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119156456-A | Method for predicting responsiveness of lymphoma to drug and method for treating lymphoma | 新基公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-4190816-A1 | ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF | Akeso Biopharma, Inc. (CN) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023090935-A1 | METHOD FOR PRODUCING AGM PEPTIDES THAT BIND SPECIFICALLY TO NUCLEOLIN | 애니젠 주식회사 | 2023-05-25 | — | — | WO | disclosed |
| US-20230158034-A1 | CO-TREATMENT WITH CDK4/6 AND CDK2 INHIBITORS TO SUPPRESS TUMOR ADAPTATION TO CDK2 INHIBITORS | PFIZER INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4132530-A1 | CO-TREATMENT WITH CDK4/6 AND CDK2 INHIBITORS TO SUPPRESS TUMOR ADAPTATION TO CDK2 INHIBITORS | Pfizer Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022258001-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | 上海岸阔医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022218384-A1 | ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF | 中山康方生物医药有限公司 | 2022-10-20 | — | — | WO | disclosed |
| CN-115192718-A | anti-CD47 monoclonal antibody and application thereof | 中山康方生物医药有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-11439646-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2022-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | CCNE1 3058/4885CDK2 1737/4885CDK1 2894/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | CCNE1 3242/4885CDK2 3195/4885CDK1 3088/4885 |
| US-20230158034-A1 | CO-TREATMENT WITH CDK4/6 AND CDK2 INHIBITORS TO SUPPRESS TUMOR ADAPTATION TO CDK2 INHIBITORS | CDK4, CDK6, CDK2 | CCNE1 52/4885CDK2 3/4885CDK1 8/4885 |
| US-11439646-B2 | Anti-proliferative agents for treating PAH | CDK8, CDK4, CDKL1 | CCNE1 82/4885CDK2 13/4885CDK1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.